Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.
Research Separations Logo

Share this

To enable the rapid progress expected of collaborative medicinal chemistry programs, Charnwood Molecular has adopted a continuous improvement approach, resulting in considerable investment in state-of-the-art equipment to streamline our workflows and better facilitate the synthesis, purification and analysis of the compounds that we prepare on behalf of our growing international client base. For purification purposes, the company’s scientists have direct access to a suite of Biotage Isolera systems, as well as a Waters mass-directed preparatory HPLC system. Routine analyses are performed at Charnwood Molecular using a combination of Waters Acquity I-Class UPLC-MS and Agilent 1260 LCMS systems.

For purification and analysis of challenging chiral targets, Charnwood Molecular collaborates with the industry-leading purification experts at Reach Separations, who are co-located in the Stuart Adams building at BioCity, Nottingham, to develop robust methods for the effective separation of chiral compounds. Reach Separations also assist Charnwood Molecular with particularly challenging achiral separations when the need arises.

Dr James Hitchin, Head of Medicinal Chemistry at Charnwood Molecular, commented: ‘Charnwood Molecular is now working in collaboration with a number of strategic partners to expedite the progression of our clients’ pre-clinical drug assets through the discovery phase and into development. We have also made significant investments in our own infrastructure, as well as recruiting new staff at different levels of our organisation, to allow us to perform as efficiently as possible, to the highest possible standards. The combination of the synthetic and medicinal chemistry expertise of our own chemists with the extensive analytical and purification capabilities provided to us by our colleagues at Reach Separations, allows us to rapidly address our clients’ demands for the delivery of high quality products to support their programs’.

Peter Ridgway, Director of Business Development at Reach Separations added: ‘At Reach Separations we like the idea that our clients view us as the virtual laboratory at the end of their corridor where they can send samples to for purification and analysis. In the case of Charnwood Molecular we are actually the lab at the end of the corridor! The two companies have established an excellent working relationship over the last five years. In some small way we have supported Charnwood Molecular in becoming more competitive in the CRO market place with a rapid turnaround of purified material and a strong level of expertise in chromatography’.

About Charnwood Molecular
Charnwood Molecular is a leading CRO providing Drug Discovery and early, pre-clinical Development services. Founded in 1998, we support the Drug Discovery activities of organisations from virtual start-ups to large Pharmaceutical companies. We offer a flexible service from the synthesis of single compounds to the full management of Medicinal Chemistry projects. For further information about Charnwood Molecular please see:

About Reach Separations
Reach Separations is a highly specialised Chromatography Purification service based at BioCity in Nottingham, UK that was founded in 2012. With a vast level of expertise in the fields of chiral, reverse phase and normal phase chromatography, Reach Separations has rapidly established itself as a key provider of Outsource purification to the pharmaceutical, fine chemical, agrochemical and academic sectors across the UK and into Mainland Europe. Please see: